Altered expression of HLA class I antigens in breast cancer: Association with prognosis

International Journal of Cancer

Volumn 89, Issue 6, 2000, Pages 500-505

  Gumundsdóttir, Ingibjörg ^a,c   Jónasson, Jón Gunnlaugur ^c   Sigursson, Helgi ^c   Ólafsdóttir, Kristrún ^c   Tryggvadóttir, Laufey ^b   Ógmundsdóttir, Helga M ^a  

^a ICELANDIC CANCER SOCIETY   (Iceland)

^b ICELANDIC CANCER REGISTRY   (Iceland)

^c UNIVERSITY OF ICELAND   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

EID: 0034693659     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001120)89:6<500::aid-ijc6>3.0.co;2-%23     Document Type: Article

References (37)

1. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
2. Repression of class I H-2K, H-2D antigens on GR9 methylcholanthrene-induced tumor cell clones is related to the level of DNA methylation
3. High frequency of altered HLA class I phenotypes in invasive breast carcinomas
4. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer
5. Can the HLA phenotype be used as a prognostic factor in breast carcinomas?
6. Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: Role for endogenous IFN-beta
7. Regulation of major histocompatibility complex class I expression by NF-kappaB-related proteins in breast cancer cells
8. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression
9. Variation of HLA-ABC surface antigen expression on adenocarcinoma of the colon in correlation with the degree of differentiation
10. Natural history of HLA expression during tumor development
11. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
12. TP53 mutation analyses on breast carcinomas: A study of paraffin-embedded archival material
13. DNA flow cytometry is a useful prognostic guide in the treatment of breast cancer
14. The immunology and immunotherapy of breast cancer: An update
15. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
16. Express yourself or die: Peptides, MHC molecules, and NK cells
17. Correlation between tumor and serum beta 2m expression in patients with breast cancer
18. Antigen presentation: Coming out gracefully
19. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival
20. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer
21. Cytokines in breast cancer: Increased levels of IL-6 and TNF-α in breast cancer patients and effects of these cytokines on breast carcinoma cells in vitro
22. Interactions between the immune system and breast cancer
23. Effects of lymphocytes and fibroblasts on the growth of human mammary carcinoma cells studied in short-term primary cultures
24. 2m) and purified class-I major histocompatibility (MHC) antigen
25. 2-microglobulin by premalignant epithelium
26. Tumor immunogenicity: How far can it be pushed?
27. Natural killer cells and recognition of MHC class I molecules: New perspectives and challenges in immunology
28. A new era for cancer immunotherapy based on the genes that encode cancer antigens
29. Cytokine (IFN-alpha, IFN-gamma, IL-1-alpha, TNF-alpha)-induced modulation of HLA cell surface expression in human breast cancer cell lines
30. Beta 2-microglobulin in non-malignant and malignant human breast: A feature of differentiation
31. Indicators of prognosis in node-negative breast cancer
32. The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer
33. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis
34. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions
35. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
36. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL- 29.1.22 and SK-MEL-29.1.29
37. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas